BRCA2 and neoplasm: Furthermore, when using VC-8 cell or VC-8 plus BRCA2 cell xenotransplantation tumor models to test sensitivity to the PP2Ai in vivo, we found that the VC-8 tumors lacking BRCA2 were more sensitive to PP2Ai treatment than those expressing wild-type BRCA2 (Figure 7C).